Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinson’s disease patients with chronic pain

Journal of Neurology

Volumn 262, Issue 9, 2015, Pages 2164-2170

  Madeo, Graziella ^a   Schirinzi, Tommaso ^a   Natoli, Silvia ^a   Pierantozzi, Mariangela ^a   Stefani, Alessandro ^a,b   Dauri, Mario ^a   Pisani, Antonio ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

Non motor symptoms; Opioid; Pain; Parkinson s disease

Indexed keywords

NALOXONE PLUS OXYCODONE; DELAYED RELEASE FORMULATION; DRUG COMBINATION; NALOXONE; OXYCODONE;

ADULT; AGED; ARTICLE; BOWEL FUNCTION INDEX; BRIEF PAIN INVENTORY; CHRONIC PAIN; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSTIPATION; DISEASE SEVERITY; DROWSINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; LOW DRUG DOSE; MALE; PAIN ASSESSMENT; PARKINSON DISEASE; PARKINSON DISEASE SLEEP SCALE 2; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; SEDATION; SIDE EFFECT; SOMNOLENCE; COMPLICATION; DELAYED RELEASE FORMULATION; DRUG COMBINATION; MIDDLE AGED; PROSPECTIVE STUDY; QUALITY OF LIFE; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CHRONIC PAIN; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NALOXONE; OXYCODONE; PARKINSON DISEASE; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84941996828     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-015-7823-3     Document Type: Article

References (23)

1. Chaudhuri KR, Odin P, Antonini A, Martinez-Martin P (2011) Parkinson’s disease: the non-motor issues. Parkinsonism Relat Disord 17:E717–E723
2. Wasner G, Deuschl G (2012) Pains in Parkinson disease: many syndromes under one umbrella. Nat Rev Neurol 8:284–941
3. Ha AD, Jankovic J (2012) Pain in Parkinson’s disease. Mov Disord 27(485e):91
4. Beiske AG, Loge JH, Ronningen A, Svensson E (2009) Pain in Parkinson’s disease: prevalence and characteristics. Pain 141:173–177
5. Gallagher DA, Lees AJ, Schrag A (2010) What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them? MovDisord 25:2493–2500
6. Martinez-Martin P (2011) The importance of non-motor disturbances to quality of life in Parkinson’s disease. J NeurolSci 310:12–16
7. Perez-Lloret S, Rey MV, Dellapina E, Pellaprat J, Brefel-Courbon C, Rascol O (2012) Emerging analgesic drugs for Parkinson’s disease. Expert Opin Emerg Drugs 17(2):157–171
8. Berg D, Becker G, Reiners K (1999) Reduction of dyskinesia and induction of akinesia induced by morphine in two parkinsonian patients with severe sciatica. J Neural Transm 106(7–8):725–728
9. Snyder C, Mantione K (2014) The effects of morphine on Parkinson’s-related genes PINK1 and PARK2. Med Sci Monit Basic Res 7(20):63–69
10. Meissner W, Leyendecker P, Mueller-Lissner S et al (2009) A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 13(1):56–64
11. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiat 55:181–184
12. Caraceni A, Mendoza TR, Mencaglia E et al (1996) A validation study of an Italian version of the Brief Pain Inventory (Breve Questionario per la Valutazione del Dolore). Pain 65(1):87–92
13. Bonezzi C, Nava A, Barbieri M, Bettaglio R, Demartini L, Miotti D, Paulin L (2002) Validazione della versione italiana del Brief Pain Inventory nei pazienti con dolore cronico. Minerva Anestesiol 68(7–8):607–611
14. Cleeland CS, Ryan KM (1994) Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap 23(2):129–138
15. Rentz AM, Yu R, Müller-Lissner S, Leyendecker P (2009) Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ 12(4):371–383
16. Quittenbaum BH, Grahn B (2004) Quality of life and pain in Parkinson’s disease: a controlled cross-sectional study. Parkinsonism Relat Disord 10:129–136
17. Roh JH, Kim BJ, Jang JH, Seo WK, Lee SH, Kim JH, Oh K, Park KW, Lee DH, Koh SB (2009) The relationship of pain and health-related quality of life in Korean patients with Parkinson’s disease. Acta Neurol Scand 119:397–403
18. Politis M, Wu K, Molloy S, Bain G, Chaudhuri P, Piccini KR (2010) Parkinson’s disease symptoms: the patient’s perspective. Mov Disord 25:1646–1651
19. Pappagallo M (2008) Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 182:S11–S18
20. Simpson K, Leyendecker P, Hopp M et al (2008) Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin 24:3503–3512
21. Löwenstein O, Leyendecker P, Hopp M et al (2009) Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother 10:531–543
22. Sandner-Kiesling A, Leyendecker P, Hopp M et al (2010) Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract 64:763–774
23. Löwenstein O, Leyendecker P, Lux EA et al (2010) Efficacy and safety of combined prolongedrelease oxycodone and naloxone in the management of moderate/severe chronic nonmalignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials. BMC Clin Pharmacol 10:12